Could a diabetes pill strengthen the right heart in lung hypertension?
NCT ID NCT06992440
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This study tests whether empagliflozin, a diabetes medicine, can improve right heart function in 78 adults with pulmonary arterial hypertension (PAH). Participants continue their usual PAH treatments and receive either empagliflozin or a placebo. The main goal is to see if the drug increases the heart's pumping ability, measured by MRI.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
The Johns Hopkins Hospital
Baltimore, Maryland, 21287, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood particles may reveal hidden clues to scleroderma complications
- Heart scans may soon replace Needle-Based catheter tests
- Could a new drug free PAH patients from daily pump therapy?
- Could pedaling backward help heart and lung patients get stronger?
- New drug aims to help lungs and heart work better during exercise
- Heart scans could spare patients from invasive catheter procedures